Page last updated: 2024-11-08

prostaglandin d2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID448457
CHEMBL ID1235252
CHEBI ID15555
SCHEMBL ID2508829
MeSH IDM0023403

Synonyms (74)

Synonym
gtpl1891
gtpl1881
[3h]prostaglandin d2
[3h]11-dehydroprostaglandin f2-alpha
[3h]-pgd2
CHEBI:15555 ,
11-dehydroprostaglandin f2-alpha
(5z,13e,15s)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid
brn 2170623
prosta-5,13-dien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5z,9-alpha,13e,15s)-
IDI1_033956
pg2 ,
LMFA03010004
9s,15s-dihydroxy-11-oxo-5z,13e-prostadienoic acid
11-dehydroprostaglandin f2alpha
bdbm21544
11-dehydroprostaglandin f2 alpha
(5z)-7-[(1r,2r,5s)-5-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoic acid
C00696
pgd2
prostaglandin d2
(5z,13e)-(15s)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
41598-07-6
(5z,13e,15s)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5z,13e)-(15s)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5e,13e)-9,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid
prostaglandin d2, >=95%, synthetic
DB02056
NCGC00161284-02
NCGC00161284-01
BSPBIO_001486
NCGC00161284-03
E8965369-341A-46F4-8677-2CEB4F9432BA
HMS1989K08
(z)-7-[(1r,2r,5s)-5-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
BML1-F05
HMS1791K08
HMS1361K08
CHEMBL1235252
rxy07s6cz2 ,
unii-rxy07s6cz2
9,15- dihydroxy-11-oxo-prosta-5,13-dien-1-oic acid, (5z,9-.alpha.,13e,15s)
prosta-glandin d2
BHMBVRSPMRCCGG-OUTUXVNYSA-N
SCHEMBL2508829
HMS3648M03
HMS3402K08
prostaglandin d2, cell culture tested
(5z,13e)-(15s)-9alpha,15-dihydroxy-11-oxoprosta-5,13-dienoic acid
(5z,9alpha,13e,15s)-9,15-dihydroxy-11-oxo-prosta-5,13-dien-1-oate
(5z,9alpha,13e,15s)-9,15-dihydroxy-11-oxo-prosta-5,13-dien-1-oic acid
(5z,13e)-(15s)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoic acid
(5z,9-alpha,13e,15s)-9,15-dihydroxy-11-oxo-prosta-5,13-dien-1-oic acid
(5z,13e,15s)-9a,15-dihydroxy-11-oxoprosta-5,13-dien-1-oate
(5z,13e)-(15s)-9a,15-dihydroxy-11-oxoprosta-5,13-dienoic acid
(5z,13e)-(15s)-9,15-dihydroxy-11-oxoprosta-5,13-dienoic acid
9s,15s-dihydroxy-11-oxo-5z,13e-prostadienoate
(5z,13e,15s)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoic acid
(5z,9-alpha,13e,15s)-9,15-dihydroxy-11-oxo-prosta-5,13-dien-1-oate
(5z,13e)-(15s)-9a,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5z,13e,15s)-9a,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid
(5z,13e,15s)-9-alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5z,13e)-(15s)-9,15-dihydroxy-11-oxoprosta-5,13-dienoate
(5z,9alpha,13e,15s)-9,15-dihydroxy-11-oxoprosta-5,13-dien-1-oic acid
AKOS032954030
DTXSID30897162
Q419750
sr-01000946237
SR-01000946237-1
HY-101988
CS-0022427
pgd2 (prostaglandin d2)
9alpha,15s-dihydroxy-11-oxo-prosta-5z,13e-dien-1-oic acid
MS-25470

Research Excerpts

Overview

Prostaglandin D2 (PGD2) is a major prostanoid produced mainly by mast cells in allergic diseases, including bronchial asthma. It is a bronchoconstriction inducing metabolite of arachidonic acid in the mast cells, which is produced on exposure to allergens.

ExcerptReferenceRelevance
"Prostaglandin D2 proved to be a potent agonist at the rat DP receptor (EC50 = 5 nM)."( A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
Ford-Hutchinson, AW; Metters, KM; Nantel, F; Wright, DH, 1999
)
1.32
"Prostaglandin D2 (PGD2) is a lipid mediator involved in sleep regulation and inflammation. "( Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2.
Aritake, K; Hamakubo, T; Ikeda, Y; Iwanari, H; Kumagai, H; Kusano-Arai, O; Nagata, N; Urade, Y, 2017
)
2.1
"Prostaglandin D2 (PGD2) is an important mediator released from activated mast cells."( Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil trafficking into the esophagus.
Wu, X; Yu, S; Zhang, S, 2014
)
2.57
"Prostaglandin D2 (PGD2) is a major prostanoid secreted mainly by mast cells. "( PGD2 deficiency exacerbates food antigen-induced mast cell hyperplasia.
Aritake, K; Choi, BI; Horiguchi, K; Iwakura, Y; Maeda, S; Maehara, T; Murata, T; Nakamura, T; Urade, Y, 2015
)
1.86
"Prostaglandin D2 (PGD2) is a major prostanoid produced mainly by mast cells in allergic diseases, including bronchial asthma. "( Prostaglandin D2 receptors DP and CRTH2 in the pathogenesis of asthma.
Arima, M; Fukuda, T, 2008
)
3.23
"Prostaglandin D2 (PGD2) is a prostanoid implicated in allergic inflammation. "( Distinct roles of prostaglandin D2 receptors in chronic skin inflammation.
Matsushima, Y; Nakamura, M; Satoh, T; Yamamoto, Y; Yokozeki, H, 2011
)
2.15
"Prostaglandin D2 (PGD2) is a bronchoconstriction inducing metabolite of arachidonic acid in the mast cells, which is produced on exposure to allergens and acts as a ligand for the Prostaglandin D2 Receptor (PTGDR)."( No association of PTGDR -441C/T polymorphism with asthma in a North Indian population.
Batra, N; Birbian, N; Jindal, SK; Joshi, A; Singh, J, 2011
)
1.09
"Prostaglandin D2 (PGD2) is a mast cell-derived mediator that seems to play a role in asthma and allergic diseases. "( 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils.
Cossette, C; Gravel, S; Monneret, G; Powell, WS; Rokach, J, 2003
)
2.15
"Prostaglandin D2 (PGD2) is a lipid mediator produced by mast cells, macrophages and Th2 lymphocytes and has been detected in high concentrations in the airways of asthmatic patients. "( Delta12-prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes.
Allan, C; Gamble, V; Gazi, L; Gyles, S; Jassal, R; Lees, S; Pettipher, R; Rose, J; Speight, G; Xue, L, 2005
)
2.21
"Prostaglandin D2 is a secondary mast cell mediator that causes redness, chemosis, mucous discharge, and eosinophil chemotaxis in the eye. "( Aspirin therapy in vernal conjunctivitis.
Abelson, MB; Butrus, SI; Weston, JH, 1983
)
1.71
"Prostaglandin D2 was found to be a potent inhibitor of B-16 melanoma cell replication in vitro. "( Inhibition of B-16 melanoma growth in vitro by prostaglandin D2.
Jaffe, BM; Simmet, T, 1983
)
1.97
"Prostaglandin D2 (PGD2) is a potent bronchoconstrictor, and is thought to have a role in the pathogenesis of asthma. "( Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor.
Freezer, NJ; Howarth, PH; Johnston, SL; O'Toole, S; Ritter, W, 1995
)
3.18
"Prostaglandin D2 (PGD2) is a very important mast cell product during the early-phase nasal allergic reaction. "( Prostaglandin D2 measurement in nasal secretions is not a reliable marker for mast cell activation in atopic patients.
Clement, P; Smitz, J; Wang, DY, 1995
)
3.18
"Prostaglandin D2 (PGD2) is an extensively studied sleep-promoting substance, but the neuroanatomical basis of PGD2-induced sleep is only partially understood. "( Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2.
Gerashchenko, D; Hayaishi, O; Onoe, H; Saper, C; Scammell, T; Urade, Y, 1998
)
1.98
"Prostaglandin D2 (PGD2) is a potent mediator in inflammatory processes."( Prostaglandin D2 inhibits fibroblast migration.
Kim, HJ; Kohyama, T; Liu, XD; Rennard, SI; Takizawa, H; Wen, FQ, 2002
)
2.48
"Prostaglandin D2 seems to be a useful drug for the treatment of patients having diaphragmatic hernias and pulmonary hypertension, and warrants further study."( Pulmonary hypertension in lambs with congenital diaphragmatic hernia: vasodilator prostaglandins, isoprenaline, and tolazoline.
Barker, AP; Ford, WD; Lee, CM; Sen, S, 1990
)
1

Effects

Prostaglandin D2 has been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) It has been established as promoting the resolution of inflammation in the gastrointestinal mucosa.

ExcerptReferenceRelevance
"Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening."( Does prostaglandin D2 hold the cure to male pattern baldness?
Garza, LA; Nieves, A, 2014
)
1.64
"Prostaglandin D2 has been established as promoting the resolution of inflammation in the gastrointestinal mucosa."( The universe of arachidonic acid metabolites in inflammatory bowel disease: can we tell the good from the bad?
Stenson, WF, 2014
)
1.12
"Prostaglandin D2 (PGD2) has marked inhibitory effects on the canine proximal colonic epithelium set up in Ussing chambers. "( Calcium-stimulated short-circuit currents in the canine proximal colonic epithelium: effects of DK-PGD2, a metabolite of prostaglandin D2.
Larsen, P; Prior, T; Rangachari, PK; Schleihauf, E; Yu, H, 2002
)
1.97
"Prostaglandin D2 has been shown to have growth inhibitory properties in several malignant cell lines."( delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
Gattoni-Celli, S; Jennerette, J; Jones, JA; McClay, EF; Winski, PJ, 1996
)
1.02

Actions

Prostaglandin D2 (PGD2) plays a crucial role in the homeostatic regulation of NREM sleep. It can cause pulmonary vasoconstriction or vasodilation depending on animal species and age.

ExcerptReferenceRelevance
"Prostaglandin D2 (PGD2 ) plays an important role in allergic inflammation. "( Role of prostaglandin D2 and CRTH2 blockade in early- and late-phase nasal responses.
Domenico, J; Gelfand, EW; Shiraishi, Y; Takeda, K, 2014
)
2.28
"(3) Prostaglandin D2 plays a crucial role in the homeostatic regulation of NREM sleep."( Genes for prostaglandin d synthase and receptor as well as adenosine A2A receptor are involved in the homeostatic regulation of nrem sleep.
Eguchi, N; Hayaishi, O; Huang, ZL; Urade, Y, 2004
)
0.8
"Prostaglandin D2 appears to inhibit fibroblast chemotaxis, perhaps by modulating the rate of fibroblast migration."( Prostaglandin D2 inhibits fibroblast migration.
Kim, HJ; Kohyama, T; Liu, XD; Rennard, SI; Takizawa, H; Wen, FQ, 2002
)
2.48
"Prostaglandin D2 (PGD2) can cause pulmonary vasoconstriction or vasodilation depending on animal species and age. "( Pulmonary vascular effects of prostaglandin D2, but not its systemic vascular or airway effects, are mediated through thromboxane receptor activation.
Banerjee, M; Biaggioni, I; Fukushima, M; Kang, KH; King, LS; Newman, JH, 1991
)
2.01

Treatment

ExcerptReferenceRelevance
"Prostaglandin D2-treated cells were the same suggesting there was no gross change in the size of the enzyme."( Prostaglandin D2 lowers nuclear DNA polymerase activity in cultured mastocytoma cells.
Kawamura, M; Koshihara, Y, 1984
)
2.43

Toxicity

ExcerptReferenceRelevance
" At least 2 weeks after completion of the study, all patients received on an open basis 25 mg rofecoxib without any adverse effects."( Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Bochenek, G; Mejza, F; Nagraba, K; Nizankowska, E; Swierczynska, M; Szczeklik, A, 2001
)
0.31
" Treatment-related adverse experiences (AEs) related to flushing, pruritis, rash, gastrointestinal upset and elevations in liver transaminases and fasting serum glucose occurred more frequently with ERN/LRPT added to statin vs."( Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Ceska, R; Giezek, H; Gil-Extremera, B; Maccubbin, D; Mao, A; McCrary Sisk, C; Paolini, JF; Shah, S; Vandormael, K, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" Mean terminal half-life values ranged from 14 to 25 hours across the dose range of 100 to 600 mg."( Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.
Bain, G; Brittain, J; Dearmond, I; Evans, JF; Hartung, JP; Holme, K; Hutchinson, JH; King, CD; Stearns, B; Truong, YP, 2012
)
0.6

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of intradermal injection of leukotriene B4 alone and in combination with prostaglandin D2 and E2 and the effect of inhaled leukotriene B4 in combination with prostaglandin D2 were studied in six non-asthmatic men."( Effect of inhaled leukotriene B4 alone and in combination with prostaglandin D2 on bronchial responsiveness to histamine in normal subjects.
Barnes, PJ; Black, PN; Dollery, CT; Fuller, RW; Taylor, GW, 1989
)
0.74
" These results demonstrate that laropiprant does not enhance in vivo platelet reactivity, either alone or in combination with niacin."( Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Chao, A; Cote, J; Dishy, V; Gutierrez, M; Lai, E; Larson, P; Laterza, O; Lauring, B; Luo, WL; Patterson, J; Wagner, JA, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" By introduction of selective enzyme inhibitors, it was determined that the bioavailability of each mediator class occurred without regulatory effects on the others."( Pharmacologic regulation of mediator generation and release from the murine bone marrow derived mast cell.
Austen, KF; Lewis, RA; Robin, JL, 1985
)
0.27
" This is also the first report detailing an orally bioavailable small molecule CRTH2 antagonist."( An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro.
Bacon, KB; Gantner, F; Iino, T; Manabe, Y; Shichijo, M; Shimazaki, M; Sugimoto, H; Watanabe, A, 2003
)
0.54
" The absolute bioavailability (BA) and sleep-inducing effect (SIE) following intranasal (IN) administration of TS-002 dry powder to cynomolgus monkeys were evaluated in comparison with intravenous (IV) administration."( Nose-to-brain delivery of TS-002, prostaglandin D2 analogue.
Hasegawa, M; Ito, S; Kametani, S; Yamada, K, 2007
)
0.62
" Finally, A-940894 has good pharmacokinetic properties, including half-life and oral bioavailability in rats and mice."( In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.
Adair, RM; Baranowski, JL; Bettencourt, BM; Brioni, JD; Brito, AA; Carr, TL; Cowart, MD; Cuff, CA; Esbenshade, TA; Liu, H; Manelli, AM; Marsh, KC; McPherson, MJ; Miller, TR; Rundell, L; Strakhova, MI; Vortherms, TA; Wetter, JM; Witte, DG; Yao, BB, 2009
)
0.35
"The bioavailability of HIV protease inhibitors is altered by P-glycoproteins (P-gp)."( High sodium butyrate levels induce MDR1 activation in colorectal cells: Impact of 15-deoxy-Δ(12,14)-prostaglandin J(2) on the resistance to saquinavir.
Dumais, N; Pasvanis, S; Tremblay, S, 2012
)
0.38

Dosage Studied

Prostaglandin D2 had biphasic effects on pain thresholds (hot plate and acetic acid writhing tests) when given in a dosage range of 5 ng to 5 micrograms per mouse. The intestinal mucosal mast cells were also indistinguishable from human lung mast cells in histamine content.

ExcerptRelevanceReference
" The highest antibiotic dosage induced an abrupt decline of PGI2 synthesis, down to 26%, in animals with the longest duration of treatment."( Prostaglandin synthesis by the lateral cochlear wall under streptomycin influence.
Aharinejad, S; Firbas, W; Franz, P; Sinzinger, H, 1992
)
0.28
" Increasing dosages of PGD2 were inhaled to establish dose-response curves that allowed determination of the provocative concentration necessary to decrease FEV1 by at least 20% (PC20) and to increase specific airway resistance (SR(aw)) by 100% (PC100)."( Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction.
Baunack, AR; Boerger, S; Magnussen, H; Templin, K, 1992
)
0.52
"Arachidonic acid (AA)- or thromboxane A2/prostaglandin H2 (TXA2/PGH2) analog (STA2 and U-46619)-induced aggregations yielded a bell-shaped dose-response curve."( Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists.
Ishikawa, Y; Ogawa, A, 1991
)
0.28
" To investigate the possible involvement of CuZnSOD gene dosage in perturbation of prostaglandin biosynthesis we analyzed transfected cells and transgenic mice that express elevated levels of human CuZnSOD."( Gene dosage of CuZnSOD and Down's syndrome: diminished prostaglandin synthesis in human trisomy 21, transfected cells and transgenic mice.
Groner, Y; Knobler, H; Minc-Golomb, D, 1991
)
0.28
" SQ 30741 had no significant effect on mean vascular pressures in the cat, and the dose-response curve for U-46619 was shifted to the right in a parallel manner with a similar apparent maximal response."( Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed.
Feng, CJ; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD, 1991
)
0.28
" Increasing concentrations (10(-7)-10(-4) M) of AH6809 (which possesses negligible intrinsic agonist activity) produced parallel shifts to the right of dose-response curves to PGD2 and ZK110841."( Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea.
Hayaishi, O; Ito, S; Negishi, M; Okuda, E; Sugama, K, 1990
)
0.28
" Dose-response curves to MCh were obtained from bronchial segments before, during, and after incubation with either a subthreshold or a threshold concentration of histamine (10(-10) or 10(-8) M), the stable TxA2 analogue U46619 (10(-11) or 10(-9) M), PGD2 (5 x 10(-9) or 5 x 10(-7) M), PGF2 alpha (10(-9) or 10(-7) M), or LTC4 (10(-11) or 10(-9) M)."( Effects of inflammatory mediators on the responsiveness of isolated human airways to methacholine.
Bonta, IL; de Jongste, JC; Jongejan, RC; Kerrebijn, KF; Raatgeep, RC; Stijnen, T, 1990
)
0.28
" With immunological activation of passively sensitized cells, histamine and PGD2 release had similar dose-response characteristics, but TXB2, LTC4, LTD4, and LTE4 release differed in reaching maximum at 50 micrograms/ml and declining at 125 micrograms/ml anti-human IgE."( The immunoglobulin E- and calcium-dependent release of histamine and eicosanoids from human dispersed mastocytosis spleen cells.
Agius, RM; Benyon, RC; Holgate, ST; Jones, DB; Robinson, C; Wright, DH, 1988
)
0.27
" The intestinal mucosal mast cells were also indistinguishable from human lung mast cells in histamine content, goat anti-human IgE dose-response curves, kinetics of histamine release, unresponsiveness to f-met peptide, and production of arachidonic acid metabolites, prostaglandin D2, and leukotriene C4."( Isolation and characterization of human intestinal mucosal mast cells.
Dvorak, AM; Fox, CC; Kagey-Sobotka, A; Lichtenstein, LM; Peters, SP, 1985
)
0.45
"2 fold rightward shift of the dose-response curve."( Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.
Hamid-Bloomfield, S; Whittle, BJ, 1989
)
0.28
" The isoproterenol-induced potentiation of the [3H]prostaglandin D2 binding gave a bell-shaped dose-response relationship (maximum response at 3 X 10(-8) M) in a stereospecific manner."( Beta 2-adrenergic regulation of prostaglandin D2 receptor in rabbit platelets.
Hanasaki, K; Ichikawa, A; Ikeda, M; Mizuno, Y; Shimonishi, M; Tomita, K; Yoshimura, S, 1987
)
0.81
" In canine basilar arteries, endothelium removal elevated the dose-response curves to 5-HT, PGF2 alpha, and PGD2, and PGE2, but not to KCl, hemoglobin, or NE."( Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries.
Hongo, K; Kassell, NF; Lee, JH; Lehman, RM; Nakagomi, T; Sasaki, T; Torner, JC, 1988
)
0.27
" In contrast, PGD2 acted as a weak and partial inhibitor in guinea-pig platelet aggregation, producing a bell-shaped dose-response relationship."( Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
Hamid, S; Whittle, BJ, 1985
)
0.62
" Bell-shaped dose-response curves were observed for the other two monkeys."( Prostaglandin D2, a cerebral sleep-inducing substance in monkeys.
Fujita, I; Hayaishi, O; Nishino, H; Onoe, H; Oomura, Y; Ueno, R, 1988
)
1.72
" LGE2, AnLGE2, delta 9-LGE2 and the synthetic epimer, 8-epi-delta 9-LGE2 all induced contractions in a dose-response fashion."( Effects of E2 levuglandins on the contractile activity of the rat uterus.
Foreman, D; Miller, DB; Salomon, RG; Zuk, L, 1987
)
0.27
" Prostaglandin D2 had biphasic effects on pain thresholds (hot plate and acetic acid writhing tests) when given in a dosage range of 5 ng to 5 micrograms per mouse."( Alterations in nociception after intracisternal administration of prostaglandin D2, E2 or F2 alpha to conscious mice.
Hayaishi, O; Horiguchi, S; Hyodo, M; Ueno, R, 1986
)
1.42
" The effect of a near-threshold dose of PGD2 on histamine dose-response relationships and on the response to a single low dose of histamine were examined."( The effect of prostaglandin D2 on the response of human skin to histamine.
Barr, RM; Greaves, MW; Koro, O; Maurice, PD, 1987
)
0.63
"The release of inflammatory mediators (histamine, PGD2, TxB2, and LTC4) from purified human lung mast cells was characterized by kinetic and anti-IgE dose-response parameters."( Characterization of inflammatory mediator release from purified human lung mast cells.
Adkinson, NF; Lichtenstein, LM; MacGlashan, DW; Peters, SP; Pinckard, RN; Schleimer, RP, 1986
)
0.27
" Dose-response curves to PGE2, PGD2, and iloprost, a PGI2 analogue, were performed before and during KATP channel blockade with glibenclamide."( Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart.
Bouchard, JF; Dumont, E; Lamontagne, D, 1994
)
0.29
" At four subsequent randomized visits, subjects received this concentration of PGD2 90 min after dosing with placebo or 20, 50 or 100 mg of BAY u 3405, a potent competitive TP receptor antagonist."( Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor.
Freezer, NJ; Howarth, PH; Johnston, SL; O'Toole, S; Ritter, W, 1995
)
1.73
" The addition of increasing concentrations of phloretin caused progressive shifts of the dose-response curves of PGF2 alpha to the right."( Phloretin as an antagonist of prostaglandin F2 alpha receptor in cultured rat astrocytes.
Baba, A; Ishibashi, T; Kitanaka, J, 1993
)
0.29
" BAY u 3405 is a potent selective competitive TP receptor antagonist, which inhibits the lower airway response to PG D2, and shifts the dose-response curve to the right by up to 16-fold."( The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage.
Harrison, J; Howarth, PH; Johnston, SL; Ritter, W; Smith, S, 1993
)
0.52
" Dose-response relations to PGD2 showed three distinct patterns: 1) a dose-dependent decrease in short-circuit current (Isc) at lower concentrations followed by a dose-dependent increase at higher concentrations; 2) dose-dependent decreases, with no increase even at the highest concentrations tested; and 3) dose-dependent increases in Isc, with no decreases at any concentration."( Biological activity of metabolites of PGD2 on canine proximal colon.
Betti, PA; Rangachari, PK, 1993
)
0.29
" In a dose-response analysis of IL-1beta and nitrite accumulation, PGD2 was seen to decrease the maximal ability of VSMCs to generate NO, arguing against competition by PGD2 at cytokine receptors."( Prostaglandin D2 inhibits inducible nitric oxide synthase expression in rat vascular smooth muscle cells.
Esumi, H; Goto, A; Kanai, F; Maeda, S; Nagoshi, H; Ogura, T; Omata, M; Shimizu, T; Toyo-oka, T; Uehara, Y, 1998
)
1.74
" Lipid microspheres and Lipiodol formulation were examined as dosage form of the PGs and lipid microspheres were selected for further study."( Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin.
Fukushima, M; Fukushima, S; Kishimoto, S; Takeuchi, Y, 2000
)
0.31
"05% zerumbone for 5 weeks, starting one week before the first dosing of AOM."( Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet.
Kohno, H; Koshimizu, K; Mori, H; Murakami, A; Ohigashi, H; Safitri, R; Shimizu, M; Takahashi, D; Tanaka, T; Tsukio, Y; Yamamoto, K; Yoshitani, S, 2001
)
0.31
" Then the rats were divided into 3 groups of 9 rats: PPAR-gamma ligand 15-deoxy-(12,14)-PGJ(2) (15d-PGJ(2)) group (15d-PGJ(2) was injected intraperitoneally at the dosage of 200 microg."( [Peroxisome proliferation-activated receptor-gamma ligands ameliorate autoimmune myocarditis associated with inhibition of T cell immunity].
Kishimoto, C; Liu, Y; Liu, ZQ; Yuan, ZY; Zhang, JJ, 2003
)
0.32
" The cells were pretreated with various doses of MTX including therapeutic dosage for RA, and then stimulated by PGD2."( Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts.
Hirade, K; Ishisaki, A; Ito, H; Kato, K; Kozawa, O; Niwa, M; Shimizu, K; Yoshida, M, 2004
)
0.64
" After 4 hours of incubation, RBL-2H3 cells cultured with RANTES at 20 ng/mL released large amounts of PGD2 in a dose-response manner compared to control."( Rat basophilic leukemia cells (RBL-2H3) generate prostaglandin D2 (PGD2) after regulated upon activation, normal T-cell expressed and secreted (RANTES) activation.
Castellani, ML; Conti, CM; Conti, P; Frydas, S; Petrarca, C; Salini, V; Shanmugham, LN,
)
0.39
" Time-course and dose-response curves showed that both receptors expressed in HEK293 cells internalized maximally after 2 h of stimulation with 1 microM PGD2."( Differential regulation of the signaling and trafficking of the two prostaglandin D2 receptors, prostanoid DP receptor and CRTH2.
de Brum-Fernandes, AJ; Gallant, MA; Hamelin, E; Parent, JL; Rochdi, MD; Slipetz, D; Talbot, S, 2007
)
0.58
" Single and multiple doses of AM211 demonstrated dose-dependent inhibition of eosinophil shape change in blood with near-complete inhibition observed at trough after dosing 200 mg once daily for 7 days."( Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.
Bain, G; Brittain, J; Dearmond, I; Evans, JF; Hartung, JP; Holme, K; Hutchinson, JH; King, CD; Stearns, B; Truong, YP, 2012
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins D
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (70)

PathwayProteinsCompounds
Developmental Biology72730
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Eicosanoid ligand-binding receptors117
Prostanoid ligand receptors75
GPCR downstream signalling17252
G alpha (i) signalling events8741
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Intracellular Signalling Through PGD2 receptor and Prostaglandin D266
Fc Epsilon Receptor I Signaling in Mast Cells4211
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Eicosanoid metabolism via cyclooxygenases (COX)137
Mammalian disorder of sexual development03
Transcriptional regulation of testis differentiation111
Prostaglandin and leukotriene metabolism in senescence619
Quercetin and Nf-kB / AP-1 induced apoptosis09
Arachidonic acid (AA, ARA) oxylipin metabolism076
Folic acid network070
Quercetin and Nf-kB / AP-1 induced cell apoptosis09
Selenium micronutrient network095
Eicosanoid synthesis026
Prostaglandin synthesis and regulation08
Arachidonic acid metabolism pathway011
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Ki0.04500.03821.41225.8000AID679943
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki0.03800.02300.07000.1490AID679658
Solute carrier organic anion transporter family member 2A1Mus musculus (house mouse)Ki0.09800.09800.10100.1040AID679648
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)K1/20.08300.08200.10780.1820AID682149
Solute carrier organic anion transporter family member 2B1Rattus norvegicus (Norway rat)Km0.03550.03550.03550.0355AID681173
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID746612Agonist activity at PPARgamma (unknown origin) transfected in HEK293 cells at 1 to 30 uM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID679658TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID746617Agonist activity at PPARdelta (unknown origin) transfected in HEK293 cells at 10 uM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID679943TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID746619Agonist activity at PPARalpha (unknown origin) transfected in HEK293 cells at 10 uM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID681173TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-07, Volume: 275, Issue:3
Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.
AID746618Agonist activity at PPARgamma (unknown origin) transfected in HEK293 cells at 10 uM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID746613Agonist activity at PPARalpha (unknown origin) transfected in HEK293 cells at 1 to 30 uM by luciferase reporter gene assay2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
AID682149TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1996The Journal of clinical investigation, Sep-01, Volume: 98, Issue:5
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).
AID681220TP_TRANSPORTER: inhibition of PGE2 uptake (PGE2: 0.015 uM) by Prostaglandin D2 at 0.15uM in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID681367TP_TRANSPORTER: uptake in Xenopus laevis oocytes2003American journal of physiology. Renal physiology, Dec, Volume: 285, Issue:6
Molecular characterization of human and rat organic anion transporter OATP-D.
AID679648TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells1999The American journal of physiology, 09, Volume: 277, Issue:3
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.
AID1346300Rat DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Nov, Volume: 307, Issue:2
Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2005The Journal of biological chemistry, Sep-16, Volume: 280, Issue:37
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2.
AID1346427Human EP4 receptor (Prostanoid receptors)2009The Journal of pharmacology and experimental therapeutics, Oct, Volume: 331, Issue:1
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands.
AID1346326Human DP2 receptor (Prostanoid receptors)2005European journal of pharmacology, Nov-07, Volume: 524, Issue:1-3
CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses.
AID1346394Human FP receptor (Prostanoid receptors)2003The Biochemical journal, Apr-15, Volume: 371, Issue:Pt 2
Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor.
AID1346336Mouse EP3 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346353Rat EP4 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346326Human DP2 receptor (Prostanoid receptors)2002British journal of pharmacology, Dec, Volume: 137, Issue:8
Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
AID1346427Human EP4 receptor (Prostanoid receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:8
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
AID1346308Human EP2 receptor (Prostanoid receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Importance of the extracellular domain for prostaglandin EP(2) receptor function.
AID1346396Rat EP3 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346377Human DP1 receptor (Prostanoid receptors)2006British journal of pharmacology, Jun, Volume: 148, Issue:3
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.
AID1346393Rat DP1 receptor (Prostanoid receptors)1999European journal of pharmacology, Jul-14, Volume: 377, Issue:1
A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
AID1346385Mouse DP1 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346318Rat EP2 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346377Human DP1 receptor (Prostanoid receptors)1999European journal of pharmacology, Jul-14, Volume: 377, Issue:1
A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor.
AID1346345Rat EP1 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346425Mouse FP receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346377Human DP1 receptor (Prostanoid receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:7
Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist.
AID1346377Human DP1 receptor (Prostanoid receptors)1995The Journal of biological chemistry, Aug-11, Volume: 270, Issue:32
Molecular cloning and characterization of the human prostanoid DP receptor.
AID1346401Mouse DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Expression and molecular pharmacology of the mouse CRTH2 receptor.
AID1346427Human EP4 receptor (Prostanoid receptors)1999Molecular pharmacology, Sep, Volume: 56, Issue:3
Importance of the extracellular domain for prostaglandin EP(2) receptor function.
AID1346326Human DP2 receptor (Prostanoid receptors)2003The Journal of pharmacology and experimental therapeutics, Nov, Volume: 307, Issue:2
Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.
AID1346326Human DP2 receptor (Prostanoid receptors)2006Molecular pharmacology, Apr, Volume: 69, Issue:4
On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,385)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990636 (18.79)18.7374
1990's676 (19.97)18.2507
2000's1236 (36.51)29.6817
2010's721 (21.30)24.3611
2020's116 (3.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.84 (24.57)
Research Supply Index8.17 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index92.16 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (53.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials78 (2.26%)5.53%
Reviews221 (6.40%)6.00%
Case Studies23 (0.67%)4.05%
Observational0 (0.00%)0.25%
Other3,132 (90.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]